Actinium Pharmaceuticals

Actinium Pharmaceuticals is a pioneer in the field of targeted radiotherapy research and development, aiming to significantly improve patient outcomes. The most advanced candidate product under development by Actinium is Actimab-A, a CD33-targeted therapy utilizing the mutation-independent α-emitter radioisotope payload Actinium-225 (Ac-225), which is expected to become a backbone therapy for acute myeloid leukemia (AML) and other myeloid malignancies.